PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2018-09-03

Date Title Company
03-Sep-2018 Global Direct-to-Consumer Genetic Testing Market Growth Insights Report 2018-2022: Consumer Education and Exploring Alternative Markets Would Drive the Direct-to-Consumer Genetic Testing Market Research and Markets
03-Sep-2018 Pixium Vision : Information on total number of voting rights and shares composing the share capital as at August 31, 2018 Pixium Vision
03-Sep-2018 Nicox: Number of voting rights as of August 31, 2018 NICOX
03-Sep-2018 Oncology Venture AS buyes 5% points Dovitinib ownership from Sass & Larsen and prolong buy back option on 30% Medical Prognosis Institute
03-Sep-2018 ThromboGenics becomes "Oxurion" ThromboGenics NV
03-Sep-2018 Acarix Clinical Advisory Board meeting held in parallel to ESC-conference in Munich, Germany, confirms validity of its comprehensive clinical study program. Acarix AB
03-Sep-2018 Cabliviā„¢ (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) Sanofi
03-Sep-2018 New Dental Practice is Eliminating the "Roadblocks" to Oral Health Roots Dental
03-Sep-2018 Mental Health Association of Frederick County Welcomes New Board Member Mental Health Association of Frederick County
03-Sep-2018 Olon Acquires Manufacturing Facility in India Olon s.p.a.
03-Sep-2018 Trading in Novo Nordisk shares by board members, executives and associated persons on 31 August 2018 Novo Nordisk A/S
03-Sep-2018 Nexstim Plc reports results of the supplementary Phase III E-FIT trial Nexstim Oyj
03-Sep-2018 Tecan successfully completes the acquisition of NuGEN Technologies Tecan Group AG
03-Sep-2018 Symphogen elects new Board members to support the Company's long-term development Symphogen A/S
03-Sep-2018 Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP) Sanofi
03-Sep-2018 Vitalnext Announces Positive Results of Clinical Study For Malnutrition Vitalnext
03-Sep-2018 Biocartis Group NV: Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China Biocartis Group NV